0 12 Antioxidants antioxidant NNS 13 20 inhibit inhibit VBP 21 29 monocyte monocyte NN 30 38 adhesion adhesion NN 39 41 by by IN 42 53 suppressing suppress VBG 54 61 nuclear nuclear JJ 62 74 factor-kappa factor-kappa NN 75 76 B B NNP 77 89 mobilization mobilization NN 90 93 and and CC 94 103 induction induction NN 104 106 of of IN 107 115 vascular vascular JJ 116 120 cell cell NN 121 129 adhesion adhesion NN 130 140 molecule-1 molecule-1 NN 141 143 in in IN 144 155 endothelial endothelial JJ 156 161 cells cell NNS 162 172 stimulated stimulate VBN 173 175 to to TO 176 184 generate generate VB 185 193 radicals radical NNS 193 194 . . . 196 200 Cell cell NN 201 209 adhesion adhesion NN 210 212 to to TO 213 224 endothelial endothelial JJ 225 230 cells cell NNS 231 241 stimulated stimulate VBN 242 244 by by IN 245 250 tumor tumor NN 251 259 necrosis necrosis NN 260 272 factor-alpha factor-alpha NN 273 274 ( ( ( 274 277 TNF TNF NNP 277 278 ) ) ) 279 281 is be VBZ 282 285 due due JJ 286 288 to to TO 289 298 induction induction NN 299 301 of of IN 302 309 surface surface NN 310 319 receptors receptor NNS 319 320 , , , 321 325 such such JJ 326 328 as as IN 329 337 vascular vascular JJ 338 342 cell cell NN 343 351 adhesion adhesion NN 352 362 molecule-1 molecule-1 NN 363 364 ( ( ( 364 370 VCAM-1 vcam-1 NN 370 371 ) ) ) 371 372 . . . 373 376 The the DT 377 388 antioxidant antioxidant JJ 389 400 pyrrolidine pyrrolidine NN 401 416 dithiocarbamate dithiocarbamate NN 417 418 ( ( ( 418 422 PDTC PDTC NNP 422 423 ) ) ) 424 436 specifically specifically RB 437 445 inhibits inhibit VBZ 446 456 activation activation NN 457 459 of of IN 460 467 nuclear nuclear JJ 468 480 factor-kappa factor-kappa NN 481 482 B B NNP 483 484 ( ( ( 484 492 NF-kappa NF-kappa NNP 493 494 B B NNP 494 495 ) ) ) 495 496 . . . 497 502 Since since IN 503 508 kappa kappa NN 509 510 B B NNP 511 517 motifs motif NNS 518 521 are be VBP 522 529 present present JJ 530 532 in in IN 533 539 VCAM-1 vcam-1 NN 540 543 and and CC 544 557 intercellular intercellular JJ 558 566 adhesion adhesion NN 567 577 molecule-1 molecule-1 NN 578 579 ( ( ( 579 585 ICAM-1 icam-1 NN 585 586 ) ) ) 587 596 promoters promoter NNS 596 597 , , , 598 600 we we PRP 601 605 used use VBD 606 610 PDTC PDTC NNP 611 613 to to TO 614 619 study study VB 620 623 the the DT 624 634 regulatory regulatory JJ 635 645 mechanisms mechanism NNS 646 648 of of IN 649 655 VCAM-1 vcam-1 NN 656 659 and and CC 660 666 ICAM-1 icam-1 NN 667 676 induction induction NN 677 680 and and CC 681 691 subsequent subsequent JJ 692 700 monocyte monocyte NN 701 709 adhesion adhesion NN 710 712 in in IN 713 724 TNF-treated tnf-treated JJ 725 730 human human JJ 731 740 umbilical umbilical JJ 741 745 vein vein NN 746 757 endothelial endothelial JJ 758 763 cells cell NNS 764 765 ( ( ( 765 771 HUVECs HUVEC NNP 771 772 ) ) ) 772 773 . . . 774 778 PDTC PDTC NNP 779 781 or or CC 782 798 N-acetylcysteine N-acetylcysteine NNP 799 803 dose dose NN 804 815 dependently dependently RB 816 823 reduced reduce VBD 824 835 TNF-induced tnf-induced JJ 836 842 VCAM-1 vcam-1 NN 843 846 but but CC 847 850 not not RB 851 857 ICAM-1 icam-1 NN 858 865 surface surface NN 866 873 protein protein NN 874 875 ( ( ( 875 879 also also RB 880 882 in in IN 883 888 human human JJ 889 898 umbilical umbilical JJ 899 907 arterial arterial JJ 908 919 endothelial endothelial JJ 920 925 cells cell NNS 925 926 ) ) ) 927 930 and and CC 931 935 mRNA mrna NN 936 946 expression expression NN 947 948 ( ( ( 948 950 by by IN 951 953 70 70 CD 953 954 % % NN 955 957 at at IN 958 961 100 100 CD 962 969 mumol/L mumol/l NN 970 974 PDTC PDTC NNP 974 975 ) ) ) 976 978 in in IN 979 985 HUVECs huvec NNS 986 988 as as IN 989 997 assessed assess VBN 998 1000 by by IN 1001 1005 flow flow NN 1006 1015 cytometry cytometry NN 1016 1019 and and CC 1020 1030 polymerase polymerase NN 1031 1036 chain chain NN 1037 1045 reaction reaction NN 1045 1046 . . . 1047 1056 Gel-shift gel-shift JJ 1057 1065 analysis analysis NN 1066 1068 in in IN 1069 1075 HUVECs huvec NNS 1076 1088 demonstrated demonstrate VBD 1089 1093 that that IN 1094 1098 PDTC PDTC NNP 1099 1108 prevented prevent VBD 1109 1117 NF-kappa NF-kappa NNP 1118 1119 B B NNP 1120 1132 mobilization mobilization NN 1133 1135 by by IN 1136 1139 TNF TNF NNP 1139 1140 , , , 1141 1151 suggesting suggest VBG 1152 1156 that that IN 1157 1161 only only RB 1162 1168 VCAM-1 vcam-1 NN 1169 1178 induction induction NN 1179 1182 was be VBD 1183 1193 controlled control VBN 1194 1196 by by IN 1197 1205 NF-kappa NF-kappa NNP 1206 1208 B. B. NNP 1209 1214 Since since IN 1215 1221 HUVECs HUVEC NNP 1222 1230 released release VBD 1231 1241 superoxide superoxide NN 1242 1248 anions anion NNS 1249 1251 in in IN 1252 1260 response response NN 1261 1263 to to TO 1264 1267 TNF TNF NNP 1267 1268 , , , 1269 1272 and and CC 1273 1277 H2O2 h2o2 NN 1278 1285 induces induce VBZ 1286 1292 VCAM-1 vcam-1 NN 1292 1293 , , , 1294 1298 PDTC PDTC NNP 1299 1302 may may MD 1303 1306 act act VB 1307 1309 as as IN 1310 1311 a a DT 1312 1319 radical radical JJ 1320 1329 scavenger scavenger NN 1329 1330 . . . 1331 1339 Although although IN 1340 1346 ICAM-1 icam-1 NN 1347 1356 induction induction NN 1357 1360 was be VBD 1361 1371 unaffected unaffected JJ 1371 1372 , , , 1373 1383 inhibitors inhibitor NNS 1384 1386 of of IN 1387 1392 NADPH NADPH NNP 1393 1400 oxidase oxidase NN 1401 1402 ( ( ( 1402 1410 apocynin apocynin NN 1410 1411 ) ) ) 1412 1414 or or CC 1415 1425 cytochrome cytochrome NN 1426 1431 P-450 P-450 NNP 1432 1433 ( ( ( 1433 1440 SKF525a SKF525a NNP 1440 1441 ) ) ) 1442 1452 suppressed suppress VBD 1453 1459 VCAM-1 vcam-1 NN 1460 1469 induction induction NN 1470 1472 by by IN 1473 1476 TNF TNF NNP 1476 1477 , , , 1478 1487 revealing reveal VBG 1488 1492 that that IN 1493 1500 several several JJ 1501 1519 radical-generating radical-generating JJ 1520 1527 systems system NNS 1528 1531 are be VBP 1532 1540 involved involve VBN 1541 1543 in in IN 1544 1547 its its PRP$ 1548 1558 regulation regulation NN 1558 1559 . . . 1560 1564 PDTC PDTC NNP 1564 1565 , , , 1566 1574 apocynin apocynin NN 1574 1575 , , , 1576 1578 or or CC 1579 1586 SKF525a SKF525a NNP 1587 1596 decreased decrease VBD 1597 1605 adhesion adhesion NN 1606 1608 of of IN 1609 1618 monocytic monocytic JJ 1619 1623 U937 u937 NN 1624 1629 cells cell NNS 1630 1632 to to TO 1633 1644 TNF-treated tnf-treated JJ 1645 1651 HUVECs huvec NNS 1652 1653 ( ( ( 1653 1655 by by IN 1656 1658 75 75 CD 1658 1659 % % NN 1660 1662 at at IN 1663 1666 100 100 CD 1667 1674 mumol/L mumol/l NN 1675 1679 PDTC PDTC NNP 1679 1680 ) ) ) 1680 1681 . . . 1682 1692 Inhibition Inhibition NNP 1693 1695 by by IN 1696 1707 anti-VCAM-1 anti-vcam-1 JJ 1708 1718 monoclonal monoclonal JJ 1719 1727 antibody antibody NN 1728 1732 1G11 1g11 NN 1733 1742 indicated indicate VBD 1743 1747 that that IN 1748 1752 U937 u937 NN 1753 1761 adhesion adhesion NN 1762 1765 was be VBD 1766 1772 VCAM-1 vcam-1 NN 1773 1782 dependent dependent JJ 1783 1786 and and CC 1787 1798 suppression suppression NN 1799 1801 by by IN 1802 1814 antioxidants antioxidant NNS 1815 1818 was be VBD 1819 1822 due due JJ 1823 1825 to to TO 1826 1833 reduced reduce VBN 1834 1840 VCAM-1 vcam-1 NN 1841 1850 induction induction NN 1850 1851 . . . 1852 1853 ( ( ( 1853 1861 ABSTRACT abstract NN 1862 1871 TRUNCATED truncated VBN 1872 1874 AT at IN 1875 1878 250 250 CD 1879 1884 WORDS words NNS 1884 1885 ) ) )